Evolución y salud: evolución experimental y epidemiología
EVOSALUD
![Foto de Evolución y salud: evolución experimental y epidemiología](/img/grupo.png)
![Foto de Stanford University](/img/noimage_org.png)
Stanford University
Stanford, Estados UnidosPublicaciones en colaboración con investigadores/as de Stanford University (6)
2018
-
Hsp90 shapes protein and RNA evolution to balance trade-offs between protein stability and aggregation
Nature Communications, Vol. 9, Núm. 1
2017
-
Significant under expression of the DosR regulon in M. tuberculosis complex lineage 6 in sputum
Tuberculosis, Vol. 104, pp. 58-64
2013
-
Hsp90 Inhibitors Exhibit Resistance-Free Antiviral Activity against Respiratory Syncytial Virus
PLoS ONE, Vol. 8, Núm. 2
2012
-
Discovery and validation of small-molecule heat-shock protein 90 inhibitors through multimodality molecular imaging in living subjects
Proceedings of the National Academy of Sciences of the United States of America, Vol. 109, Núm. 37
2007
-
Evolutionary constraints on chaperone-mediated folding provide an antiviral approach refractory to development of drug resistance
Genes and Development, Vol. 21, Núm. 2, pp. 195-205
2006
-
The chaperonin TRiC controls polyglutamine aggregation and toxicity through subunit-specific interactions
Nature Cell Biology, Vol. 8, Núm. 10, pp. 1155-1162